Around 425 million individuals globally are affected by diabetes, with about 75 million of them relying on daily insulin injections. Now, a groundbreaking
Hyderabad-based NiedlFree Technologies has developed a needle-free oral insulin spray called Ozulin, offering a painless alternative for diabetes treatment. The company has obtained global patents for Ozulin in over 40 countries and has applied for permission to conduct safety studies. NiedlFree Technologies is also working on oral and nasal sprays for cancer, osteoporosis, and Alzheimer's.
/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...
/PRNewswire/ -- As per Zion Market Research study, The global needle-free diabetes care market size was worth USD 9.1 billion in 2021 and is estimated to grow...
Share this article
Share this article
ResearchAndMarkets.com's offering.
The "Global Oral Insulin Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report provides an in depth analysis of the global oral insulin market by value, by region, etc.
The treatment with oral insulin offers several advantages, such as higher patient compliance; rapid hepatic insulinization, and avoidance of peripheral hyperinsulinemia and other adverse effects such as possible hypoglycemia and weight gain.
The report also provides a detailed analysis of the COVID-19 impact on the oral insulin market.
The oral insulin market can be segmented on the basis of application (Type 1 diabetes and Type 2 diabetes); and gender (Female and Male).